ESA Mortality Risk Prediction via Hemoglobin Degradation Rate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating anemia with Erythropoiesis Stimulating Agents (ESAs) in patients with cancer, chemotherapy, chronic kidney disease (CKD), or chronic inflammation lack the ability to accurately predict individual patient responses, leading to adverse events such as mortality and thromboembolic events due to insufficient sensitivity in baseline parameters and lack of patient-specific predictive values.
Innovation Solution
A method involving the determination of individual hemoglobin degradation rate, ESA binding sites, and ESA dose to calculate an accumulated risk factor, which stratifies patients into high or low risk groups for adverse events, using a non-linear dynamic pharmacokinetic ESA-EPO-R pathway model to assess ESA binding properties and hemoglobin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If linear or logistic regression models are used to predict patient responses from clinical markers, then prediction capability is provided, but sensitivity for individualized prediction is insufficient
Solution Approach 1:
The patent changes from using standard clinical markers to using dynamic Hb degradation rate and ESA binding site number as predictive parameters. This parameter transformation enables individualized prediction by capturing patient-specific physiological responses to ESA treatment, thereby improving both prediction sensitivity and reliability for mortality risk assessment.
2Device complexity
If baseline parameters and their combinations are used for prediction, then prediction approach is simple, but predictive sensitivity for individual patients is insufficient
Solution Approach 1:
The patent performs preliminary determination of Hb degradation rate and ESA binding site number before risk assessment. This preliminary action captures individual patient characteristics early in treatment, enabling sensitive individualized prediction without requiring complex longitudinal modeling, thus balancing simplicity with predictive precision.
3Duration of action of stationary object
If ESA treatment is continued without risk assessment, then anemia treatment continuity is maintained, but adverse events such as mortality and thromboembolic events occur
Solution Approach 1:
The patent implements feedback by continuously monitoring Hb levels to calculate Hb degradation rate and ESA binding site number, then using these parameters to assess mortality risk and adjust ESA treatment accordingly. This feedback mechanism enables treatment continuity while preventing adverse events through dynamic risk-adjusted dosing decisions.
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
The present invention pertains to the diagnosis of a high risk of mortality or other adverse events in a patient suffering from anemia, for example anemia caused by chemotherapy, cancer or chronic inflammation such as chronic kidney disease (CKD). The invention provides means to diagnose a patient who receives Erythropoiesis Stimulating Agents (ESA) and suffer from an adverse event if the treatment with the ESA is continued. Based on the herein disclosed methods, the clinician will be able to diagnose the prevalence of a fatal event and adjust the treatment of the anemia in the patient accordingly.